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BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors 
(TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined 
mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC 
trial. Risk of mortality and disease progression was lower in patients with high BIM compared 
with low/intermediate BIM mRNA levels. Analysis of MTOR further divided patients with high BIM 
expression into two groups, with those having both high BIM and MTOR experiencing shorter 
overall and progression-free survival to erlotinib. Validation of our results was performed in an 
independent cohort of 19 patients with EGFR-mutant NSCLC treated with EGFR TKIs. In EGFR-
mutant lung adenocarcinoma cell lines with high BIM expression, concomitant high mTOR expression 
increased IC50 of gefitinib for cell proliferation. We next sought to analyse the signalling pattern 
in cell lines with strong activation of mTOR and its substrate P-S6. We showed that mTOR and 
phosphodiesterase 4D (PDE4D) strongly correlate in resistant EGFR-mutant cancer cell lines. These 
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data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate 
therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.
Since the introduction of erlotinib and gefitinib into clinical practice, metastatic epidermal growth factor 
receptor (EGFR) positive lung cancer patients can be offered therapeutic alternatives with proven supe-
riority over platinum-based chemotherapy1,2. The EURTAC trial demonstrated efficacy of erlotinib over 
chemotherapy for first-line treatment of European advanced EGFR-mutant non-small-cell lung cancer 
(NSCLC) patients1. However, many patients have no response at all and response is short-lived for most 
of those who do. The emergence of the T790M EGFR gatekeeper mutation or activation of bypass sig-
nalling pathways have been identified as the main mechanisms of resistance to EGFR tyrosine kinase 
inhibitors (TKI)3,4.
It is recognized that TKIs eliminate tumour cells by inducing a form of cell death called apoptosis, 
which is governed by the B-cell lymphoma protein 2 (Bcl-2) family of proteins and mitochondria5. The 
Bcl-2 family is composed of two types of proteins; anti-apoptotic members like Bcl-2, Bcl-xL and Mcl-1 
and pro-apoptotic members divided into effectors and BH3-only proteins. The Bcl-2 interacting medi-
ator of cell death (BIM) is a BH3-only protein that directly activates the ultimate effectors of apoptosis 
BAK (BCL-2 antagonist or killer) and BAX (BCL-2-associated X protein)6. EGFR mutations activate 
mitogen-activated protein kinase (MAPK)/ extracellular signal–regulated kinase 1/2 (ERK1/2) and phos-
phatidylinositol 3′ -kinase-AKT (PI3K/AKT) pro-survival pathways. BIM, a well-known target of MAPK 
Figure 1. The relationship between the EGFR pathway, apoptosis and the DGKα -PDE4-cAMP-mTOR 
pathway was designed using the Ingenuity Pathway Analysis (IPA) software (https://www.ingenuity.
com/). EGFR stimulates intracellular signalling cascades, such as the RAS/RAF/ERK (MAPK) pathway—
which induces BIM proteosomal degradation—and the PI3K/AKT/mTOR pathway. mTOR nucleates a 
rapamycin and nutrient -sensitive multiprotein complex called mTORC1, and a second growth-factor-
sensitive but nutrient-insensitive mTOR-containing complex called mTORC2. Besides mTOR, mTORC1 
contains Raptor, mLST8 (also known as Gβ L), and PRAS40 (proline-rich AKT substrate 40 kDa). mTORC2, 
like mTORC1, also includes the mLST8 protein, but instead of Raptor, mTORC2 contains the Rictor and 
mammalian stress-activated protein kinase [SAPK]-interacting (mSIN1) proteins. mTORC2 also contains 
Protor (protein observed with RICTOR). Ribosomal S6 kinase 70kDa (p70S6K) and eIF4E-binding protein 
1 (4EBP1)—both regulators of mRNA translation—are the only extensively described mTORC1 substrates. 
Phosphorylation of the translational repressor 4EBP1 results in its dissociation from the eukaryotic initiation 
factor 4E (eIF4E), thereby allowing eIF4E to assemble with other translation initiation factors and initiate 
cap-dependent translation. mTORC2 directly phosphorylates and activates AKT. BIM activates BAK and 
BAX, causing activation and mitochondrial outer membrane permeabilization (MOMP). Anti-apoptotic 
BCL-2 proteins prevent MOMP by binding BIM and other BH3-only proteins as well as activated BAX or 
BAK. Following MOMP, release of various proteins from the mitochondrial intermembrane space promotes 
caspase activation and apoptosis. DGKα is a lipid kinase that phosphorylates the lipid diacylglycerol (DAG), 
transforming it into phosphatidic acid. Phosphatidic acid activates mTOR signalling via a unique pathway 
involving cAMP. The cAMP-degrading PDE4 enzymes also activate mTOR signalling. mTORC1 promotes 
survival through translational control of Mcl-1.
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signalling, is a mediator of tumour cell death in response to targeted therapies7 (Fig.  1). Faber et al., 
were the first to demonstrate that patients with EGFR-mutant NSCLC and low BIM expression derive 
less clinical benefit from EGFR inhibitors5. We identified high levels of BIM mRNA expression as a pre-
dictive marker of response, progression-free survival (PFS) and overall survival (OS) in erlotinib-treated 
EGFR-mutant NSCLC patients8.
RAF or MEK inhibitors inhibit ERK phosphorylation (P-ERK) and induce BIM levels in BRAF-mutant 
melanoma cell lines. In resistant melanoma cell lines, vemurafenib (BRAF inhibitor) or selumetinib 
(MEK inhibitor) either fail to suppress P-ERK or resistance emerges through the activity of mammalian 
target of rapamycin (mTOR), despite P-ERK suppression and BIM induction9. This suggests that BIM 
regulation is MAPK-dependent, but mTOR-independent, and BIM up-regulation is not always suffi-
cient to promote apoptosis9. Combining vemurafenib with an mTOR or PI3K inhibitor improved cell 
killing in BRAF-mutant melanomas with ERK-independent resistance to MAPK inhibition9. mTOR, a 
multifunctional 293-kDa serine/threonine protein kinase encoded by the gene MTOR, is a downstream 
effector of PI3K/AKT and promotes cell growth, division, angiogenesis and metabolic reprogramming9. 
The mTOR kinase serves as the catalytic subunit of two multiprotein complexes with distinct func-
tions: mTOR complex 1 (mTORC1), a rapamycin and nutrient-sensitive complex, defined by the regula-
tory associated protein of mTOR (Raptor), and mTOR complex 2 (mTORC2), a growth-factor-sensitive 
but nutrient-insensitive complex, defined by the rapamycin-insensitive companion of mTOR (Rictor) 
(Fig. 1)10.
The activity of mTORC1 is regulated by the integration of many signals. For instance, increases in cir-
culating branched-chain amino acids as a result of a high-fat diet, induce mTOR signalling independent 
of PI3K signalling11. In glioblastoma and melanoma cells, diacylglycerol kinase α (DGKα ), a lipid kinase 
converting diacylglycerol to phosphatidic acid, regulates both mTOR activity and MTOR mRNA levels 
via modulation of cyclic adenosine monophosphate (cAMP) (Fig. 1)12,13. The inhibitory effect of cAMP 
on mTOR can be also neutralized by phosphodiesterase 4 (PDE4), an enzyme in which two of four iso-
forms (PDE4A and PDE4D) are increased under hypoxia in lung adenocarcinoma cell lines (Fig. 1)13,14. 
Once activated, mTORC1 phosporylates ribosomal S6 kinase 70 kDa (p70S6K) and eIF4E-binding pro-
tein 1 (4EBP1) to promote cap-dependent translation and cell growth (Fig. 1).
To further understand the clinical implications of mTOR in EGFR-mutant patients, we assessed 
baseline mRNA levels of MTOR by quantitative real-time polymerase chain reaction (qRT-PCR) in 57 
EGFR-mutant erlotinib or chemotherapy treated NSCLC patients from the EURTAC trial from whom 
tumour tissue was available8. Herein we present updated results of the correlation of BIM mRNA alone 
and in combination with MTOR with OS, PFS and response in these 57 EGFR-mutant NSCLC patients 
(training cohort). An independent group of 19 EGFR-mutant patients treated with EGFR TKIs was 
included in the study as a validation cohort for which BIM expression and the phosphorylation state of 
ribosomal protein S6 (P-S6) were additionally determined by immunohistochemistry. Finally, BIM and 
mTOR expression were determined in our panel of EGFR-mutant lung adenocarcinoma cell lines and 
correlated with the half maximal inhibitory concentration (IC50) of gefitinib. We investigated the effect 
of gefitinib treatment on BIM expression and mTOR expression and activity. DGKa, PDE4A and PDE4D 
expression were examined in our cell lines and the results correlated with mTOR expression.
Results
The EURTAC study enrolled 173 patients with EGFR mutations who were randomized to receive erlo-
tinib or standard intravenous chemotherapy with cisplatin or carboplatin plus docetaxel or gemcitabine1. 
Pretreatment tumour specimens were available from 57 of these patients for assessment of MTOR mRNA 
expression. Table 1 shows patient characteristics of the 57 patients included in the present subanalysis. 
The EURTAC was approved by the Institutional Review Board of each participating centre and written 
informed consent was obtained from all patients. Among the 48 patients whose MTOR mRNA was suc-
cessfully examined, MTOR expression was low (< 0.91) or intermediate (0.91–1.97) in 30 (62.5%) and 
high (> 1.97) in 18 (37.5%). Among the 54 patients whose BIM mRNA was successfully examined, BIM 
expression was low (< 1.83) or intermediate (1.83–2.96) in 36 (66.7%) and high (> 2.96) in 18 (33.3%). 
Evaluation of the expression levels of both MTOR and BIM was possible in 46 patients.
An independent group of 19 EGFR-mutant NSCLC patients receiving erlotinib, gefitinib or afati-
nib from 2009 to 2014 in Spain, Italy and Colombia was included in the study as a validation cohort. 
Supplementary Table 1 shows patient characteristics of those 19 patients. Material was available for 
mRNA analysis of BIM and MTOR for all of them; BIM and MTOR mRNA expression was successfully 
examined in all of them. MTOR expression was low (< 0.91) or intermediate (0.91–1.97) in 15 (83.3%) 
and high (> 1.97) in 3 (16.7%). BIM expression was low (< 1.83) or intermediate (1.83–2.96) in 12 
(63.2%) and high (> 2.96) in 7 (36.8%). Material was available for immunohistochemical analysis of 
BIM and P-S6 for all 19 patients of the validation cohort and was successfully examined in all of them. 
Although not statistically significant, a trend for a positive correlation was found between BIM mRNA 
and protein expression (Wilcoxon test two-side P value = 0.1161) as well as MTOR mRNA and P-S6 
expression (Wilcoxon test two-side P value = 0.4048) (Supplementary Fig. 1a,b).
Progression-free survival. On December 9th 2013, median PFS for the 57 patients was 9.7 months 
(95% confidence intervals [CI], 3.0-13.2) in the erlotinib arm and 6.3 months (95% CI, 5.1–8.3) in the 
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chemotherapy arm P = 0.0265). Among the 29 patients treated with erlotinib, PFS was significantly longer 
for those with high BIM than for those with low/intermediate BIM mRNA expression 18.5 months, 95% 
CI, 9.7-not reached [NR] versus [vs] 3.6 months, 95% CI, 1.9–10.4; P = 0.0145) (Fig. 2a). No significant 
differences in PFS were observed according to MTOR mRNA levels. Among the seven erlotinib treated 
patients with high BIM and evaluable MTOR expression levels, median PFS was NR (95% CI, 9.7-NR) for 
those with low/intermediate MTOR vs 9.7 months (95% CI, NR) for those with high MTOR (P = 0.0894). 
MTOR did not affect PFS in patients with low/intermediate BIM (Fig.  2b). In the univariate analysis, 
erlotinib (hazard ratio [HR] = 0.48; 95% CI, 0.25–0.93; P = 0.0265) and high BIM expression (HR = 0.40; 
95% CI, 0.20–0.80; P = 0.0095) were associated with longer PFS (Supplementary Table 2). In the multi-
variate analysis, they both remained markers of longer PFS; HR = 0.49; 95% CI, 0.25–0.96; P = 0.0387 
and HR = 0.39; 95% CI, 0.19–0.78; P = 0.0079 respectively.
With a median follow up of 21.65 (range 3–58) months, median PFS was 13.0 months (95% CI, 
8.2–14.9) for the 19 patients of the validation cohort. PFS was significantly longer for those with high 
BIM than for those with low/intermediate BIM mRNA expression (15.0 months, 95% CI, 2.6–22.0 vs 9.2 
months, 95% CI, 5.4–14.1; P = 0.02) (Fig. 2c). No significant differences in PFS were observed according 
to MTOR mRNA expression. Among the 7 patients with high BIM, PFS was longer for the four patients 
Erlotinib 
(N = 29)
Chemotherapy 
(N = 28) Total (N = 57) P Value Test
Sex N(%)
 Female 19 (65.5) 21 (75.0) 40 (70.2) Chi-Square: 0.4340
 Male 10 (34.5) 7 (25.0) 17 (29.8)
Age N(%)
 < 65 years 15 (51.7) 12 (42.9) 27 (47.4) Chi-Square: 0.5027
 > = 65 years 14 (48.3) 16 (57.1) 30 (52.6)
Smoking status N(%)
 Never smoked 15 (51.7) 19 (67.9) 34 (59.7) Fisher: 0.2416
 Former smoker 12 (41.4) 6 (21.4) 18 (31.6)
 Current smoker 2 (6.9) 3 (10.7) 5 (8.8)
ECOG PS* N(%)
 0 9 (31.0) 11 (39.3) 20 (35.1) Fisher: 0.5693
 1 15 (51.7) 15 (53.6) 30 (52.6)
 2 5 (17.2) 2 (7.1) 7 (12.3)
Histologic Diagnosis N(%)
 Adenocarcinoma 28 (96.6) 24 (85.7) 52 (91.2) Fisher: 0.1086
 Bronchioalveolar adenocarcinoma 0 (0.0) 1 (3.6) 1 (1.8)
 Large-cell carcinoma 1 (3.5) 0 (0.0) 1 (1.8)
 Other 0 (0.0) 3 (10.7) 3 (5.3)
Clinical Stage N(%)
 IIIB (malignant effusion) 4 (13.8) 1 (3.6) 5 (8.8) Fisher: 0.3516
 IV 24 (82.8) 27 (96.4) 51 (89.5)
 Unknown 1 (3.5) 0 (0.0) 1 (1.8)
Bone metastasis N(%)
 Yes 7 (24.1) 9 (32.1) 16 (28.1) Chi-Square: 0.5013
 No 22 (75.9) 19 (67.9) 41 (71.9)
Brain metastasis N(%)
 Yes 4 (13.8) 4 (14.3) 8 (14.0) Fisher: 1.0000
 No 25 (86.2) 24 (85.7) 49 (86.0)
Type of EGFR mutation N(%)
 del19 18 (62.1) 19 (67.9) 37 (64.9) Chi-Square: 0.6471
 L858R 11 (37.9) 9 (32.1) 20 (35.1)
Table 1.  Patient characteristics of the 57 patients included in the present study. *ECOG, Eastern 
Cooperative Oncology Group.
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with low/intermediate MTOR than for the three with high MTOR (18.5 months, 95% CI, 14.2.0–53.1 vs 
13.0 months, 95% CI, 2.6–15.8; P = 0.0939) (Supplementary Fig. 2d).
Overall survival. On December 9th 2013, with median follow-up of 49.4 months, median OS for the 
57 patients was 22.5 months (95% CI, 14.0–30.0) in the erlotinib arm vs 22.1 months (95% CI, 15.4–
40.1) in the chemotherapy arm (P = 0.4303). OS was significantly longer for the 18 patients with high 
BIM than for the 36 with low/intermediate BIM mRNA expression (40.1 months, 95% CI, 14.6–63.0 vs 
17.7 months, 95% CI, 13.2–26.8; P = 0.010) (Supplementary Fig. 2a). No significant differences in OS 
were observed according to MTOR mRNA levels. Among the 14 patients with high BIM and evalua-
ble MTOR expression levels, OS was longer for the 11 patients with low/intermediate MTOR than for 
the three with high MTOR, though differences were not statistically significant (40.1 months, 95% CI, 
Figure 2. Progression-free survival by BIM and MTOR mRNA expression levels in the training and 
validation cohort of patients (a). Progression free survival to erlotinib according to BIM mRNA levels for 
the 27 erlotinib treated patients of the training cohort. Median PFS was 18.5 months (95%CI 9.7-NR) for 
the nine patients with high BIM (red line) and 3.6 months (95%CI 1.9–10.4) for the 18 patients with low 
BIM mRNA expression (blue line); P = 0.0145; (b) Progression-free survival by BIM and MTOR mRNA 
levels in 23 EGFR-mutant erlotinib-treated NSCLC patients of the training cohort whose BIM and MTOR 
mRNA could be evaluated. Median PFS was 6.9 months (95%CI 0.1–18.8) for the nine patients (G1) with 
low/intermediate BIM and MTOR and 4.2 months (95%CI 1.6-10.4) for seven patients (G2) with low/
intermediate BIM and high MTOR. Median PFS was NR (95%CI 9.7-NR), for five patients (G3) with high 
BIM and low/intermediate MTOR and 9.7 months (95%CI NR) for the only two patients (G4) with high 
BIM and MTOR.; P = 0.0894. (c) Progression free survival to EGFR TKIs according to BIM mRNA levels 
in the 19 EGFR-mutant patients of the validation cohort. Median PFS was 15.0 months, (95% CI, 2.6–22.0) 
in the seven patients with high BIM (red line) and 9.2 months, (95% CI, 5.4-14.1) for the 12 patients with 
low BIM mRNA expression (blue line); P = 0.02. (d) Progression-free survival by BIM and MTOR mRNA 
levels in 19 EGFR-mutant NSCLC patients of the validation cohort, treated with EGFR TKIs, whose BIM 
and MTOR mRNA could be evaluated. Median PFS was 9.9 months (95%CI 5.4–14.1) for the 11 patients 
(G1) with low/intermediate BIM and MTOR and 8.2 months (95%CI NR) for one patient (G2) with low/
intermediate BIM and high MTOR. Median PFS was 18.5 months (95%CI 14.2–53.1), for four patients (G3) 
with high BIM and low/intermediate MTOR and 13.0 months (95%CI 2.6–15.8) for the three patients (G4) 
with high BIM and MTOR; P = 0.0939. Note: BIM expression levels were divided into high (> 2.96), low 
(< 1.83) or intermediate (1.83–2.96). MTOR expression levels were divided into high (> 1.97), low (< 0.91) 
or intermediate (0.91–1.97).
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8.6-NR vs 20.3 months, 95% CI, 18.1–22.5; P = 0.4848). MTOR did not affect OS in patients with low/
intermediate BIM (Supplementary Fig. 2b). In the univariate analysis for OS, high BIM mRNA expres-
sion was associated with longer OS (HR = 0.39; 95% CI, 0.19–0.82; P = 0.0124), and presence of brain 
metastases with shorter OS (HR, 2.66; 95% CI 1.10–6.43; P = 0.0293) (Supplementary Table 2). In the 
multivariate analysis, only high BIM expression (HR = 0.43; 95% CI, 0.20–0.90; P = 0.026) remained a 
marker of longer OS.
Median OS was 21.6 months (95% CI, 13.2-NR) for the 19 patients of the validation cohort. Though 
not statistically significant, OS was longer for the 7 patients with high BIM than for the 12 with low/
intermediate BIM mRNA expression (39.2 months, 95% CI, 2.7-NR vs 21.1 months, 95% CI, 12.4-NR; 
P = 0.66). No significant differences in OS were observed according to MTOR mRNA levels. Among the 
seven patients with high BIM mRNA expression, OS was not reached for the four with low/intermediate 
MTOR compared to 15.8 months (95% CI, 13.0–19.0) for the three with high MTOR mRNA expression 
(P = 0.0093).
Response. When the 57 EGFR-mutant NSCLC patients of the training cohort were grouped as erlo-
tinib responders and non-responders according to BIM mRNA expression, a clear trend emerged: 88.9% 
of patients with high BIM mRNA expression responded to erlotinib vs 22.2% of patients with low/inter-
mediate BIM levels (P = 0.0027).
When the 19 EGFR-mutant NSCLC patients of the validation cohort were grouped as EGFR TKI 
responders and non-responders according to BIM mRNA expression, 85.72% of patients with high BIM 
responded to EGFR TKIs vs 50.0% patients with low/intermediate BIM (P = 0.3240). No differences in 
response to EGFR TKIs were observed according to MTOR mRNA expression in either the training or 
the validation cohort.
BIM and mTOR expression and in vitro sensitivity to gefitinib. We examined the in vitro sensi-
tivity of five EGFR-mutant lung adenocarcinoma cell lines to gefitinib (Table 2). Gefitinib-sensitive PC-9 
cells harbour a small in-frame deletion in exon 19 that leads to elimination of an LREA motif in the 
protein (Del E746–A750). Gefitinib-sensitive H3255 and 11–18 cells harbour a point mutation in exon 
21 that substitutes an arginine for leucine at position 858 in the protein (L858R). Gefitinib-insensitive 
H1975 and H1650 cells, although harbouring the same kinase domain mutations (L858R and Del E746–
A750), have additional changes such as T790M (H1975) or phosphatase and tensin homologue (PTEN) 
loss (H1650).
By matching cell line sensitivity to BIM and mTOR expression, we observed that inhibition concen-
tration of 50% cell viability (IC50) induced by gefitinib was increased as mTOR expression increased, in 
the three sensitive and high BIM expressing EGFR-mutant lung adenocarcinoma cell lines, H3255, PC-9 
and 11–18. In fact, H3255 cells with high BIM and low mTOR expression (both protein and mRNA) are 
hypersensitive to gefitinib, yielding IC50 values at 10-fold lower concentrations compared to PC-9 and at 
100-fold lower concentrations compared to 11–18 (Fig. 3).
To test the ability of gefitinib to induce BIM and inhibit mTOR expression in EGFR-mutant cells, we 
treated cells with gefitinib and performed western blotting and qRT-PCR. Treatment of PC-9 and H3255 
cells with gefitinib increased BIM protein expression even at a concentration of 5nM. However changes 
in mTOR expression levels were not observed in these cells (Fig.  4a). Treatment of PC-9 cells with 
gefitinib increased BIM mRNA expression in a dose- and time-dependent manner but MTOR expres-
sion was not affected (Fig.  4b). In contrast, gefitinib changed neither BIM nor mTOR expression in 
the less gefitinib-sensitive 11–18 cells as well as the gefitinib-resistant H1975 and H1650 cells (Fig. 4c). 
Furthermore in PC-9 and H3255 cells, gefitinib treatment inhibited the phosphorylation of mTOR and 
p70S6K, while phosphorylation levels of mTOR and p70S6K could not be inhibited below basal levels in 
11–18, H1975 and H1650 cells (Fig. 5).
In an exploratory analysis, the protein and mRNA expression levels of DGKa, PDE4A and PDE4D 
were examined in the five EGFR-mutant lung adenocarcinoma cell lines in an effort to explore whether 
DGKa regulates MTOR transcription through modulation of cAMP levels. We also wished to elucidate the 
role of PDE4 as the predominant cAMP-degrading enzyme. Immunoblotting confirmed that the protein 
Cells Mutation IC50* (μM)
H3255 L858R 0.003
PC-9 Del E746–A750 0.04
11–18 L858R 0.39
H1975 L858R, T790M 9.07
H1650 Del E746–A750 13.67
Table 2.  IC50 values for gefitinib as determined by MTT assay in our panel of EGFR-mutant cell lines. 
*IC50: inhibition concentration of 50% cell viability.
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levels of PDE4D and mTOR are similarly increased in 11–18, H1975 and H1650 cells (Supplementary 
Fig. S3a). By qRT-PCR, MTOR mRNA expression showed significant positive correlation with PDE4D 
mRNA expression, with a Pearson correlation coefficient of r = 0.92; P = 0.0244 (Supplementary Fig. 
S3b).
Discussion
Although expression and degradation of BIM are regulated mainly by the MAPK pathway, a variety 
of other mechanisms can also regulate BIM function, including transcriptional and posttranscrip-
tional regulation to posttranslational modification and epigenetic silencing3. For instance, an inverse 
relationship has been reported between miR-494 and BIM expression15. AKT may also phosphoryl-
ate and suppress the BIM transcription factor FOXO33,16. Our findings highlight that pre-treatment 
assessment of BIM levels is able to identify EGFR-mutant patients who will benefit more from EGFR 
TKI treatment.
An additional aim of our study was identification of MAPK-independent mechanisms that may not 
affect BIM induction but may still affect efficacy of EGFR TKI monotherapy. Among the 29 patients of 
the training cohort treated with erlotinib, PFS was 18.5 months for those with high BIM compared with 
3.6 months for those with low/intermediate BIM mRNA expression (P = 0.0145). Median PFS was not 
reached for patients with high BIM and low/intermediate MTOR compared to 9.7 months for those with 
both high BIM and MTOR, though differences were not statistically significant (P = 0.0894).
In the validation cohort of 19 patients receiving treatment with erlotinib, gefitinib or afatinib, PFS 
was 15.0 months for those with high BIM compared with 9.2 months for those with low/intermediate 
BIM mRNA expression (P = 0.02). Among the 7 patients with high BIM and evaluable MTOR expression 
levels, PFS was 18.5 months for the four patients with low/intermediate MTOR compared to 13.0 months 
for the three with high MTOR, though differences were not statistically significant (P = 0.0939).
Interestingly, when we matched gefitinib sensitivity to BIM and mTOR mRNA and protein expression 
in EGFR-mutant lung adenocarcinoma cell lines, we observed that the IC50 values of gefitinib increase 
Figure 3. The IC50 values for gefitinib in EGFR-mutant lung adenocarcinoma cell lines are associated 
with basal BIM and mTOR expression (protein or mRNA). (a) mTOR and BIM expression in EGFR-
mutant lung adenocarcinoma cell lines. Lysates were prepared and run on gels for western blot with 
specific antibodies. Actin was used as the loading control. Among the three sensitive EGFR-mutant lung 
adenocarcinoma cell lines, H3255, PC-9 and 11–18, 11–18 is the one with the highest mTOR and BIM 
protein expression. (b) MTOR and BIM mRNA expression in EGFR-mutant lung adenocarcinoma cell 
lines by qRT-PCR normalized to β -actin. Among the three sensitive EGFR-mutant lung adenocarcinoma 
cell lines, H3255, PC-9 and 11–18, 11–18 has the highest MTOR and BIM mRNA expression. PC-9, 11–18 
and H1975 cells have high BIM mRNA expression. H1650 cells have low BIM mRNA expression. The two 
gefitinib resistant EGFR-mutant lung adenocarcinoma cell lines, H1975 and H1650, have intermediate and 
high MTOR mRNA expression levels, respectively. Values are the mean ± standard deviation of triplicate 
experiments. *BIM low, < 1.83; BIM intermediate, 1.83-2.96; BIM high, > 2.96; MTOR low, < 0.91; **MTOR 
intermediate, 0.91-1.97; and MTOR high, > 1.97. Error bars indicate the standard deviation. (c). The IC50 
values for gefitinib increase in the three sensitive EGFR-mutant lung adenocarcinoma cell lines, H3255, PC-9 
and 11–18, as mTOR expression increases (protein or mRNA). 11–18 are sensitive cells with the highest 
mTOR expression and IC50 value for gefitinib 0.39 μ M, a concentration more than 100-fold higher compared 
to H3255 cells that have the lowest mTOR expression and are hypersensitive to gefitinib (IC50 0.003 μ M).
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as the mTOR levels increase in the three sensitive and high BIM expressing cell lines (PC-9, H3255 and 
11–18 in Fig. 4). In cells with high mTOR expression, gefitinib did not induce BIM expression and did 
not suppress mTOR activity (11–18, H1975 and H1650 in Figs 4c and 5b).
mTOR serves as a key signalling hub that integrates signals from several important upstream path-
ways, making it a bona fide target for molecular therapy17. RAF and MEK inhibitor combination has 
been found to be less effective in BRAF-mutant melanoma tumours with MAPK-independent resistance 
in which ERK is adequately suppressed but alternatively mTOR is activated as estimated by the phospho-
rylation of p70S6 kinase 1 (S6K1)9. Additionally mTOR activity can predict sensitivity of PIK3CA-mutant 
breast tumours to PI3K p110α inhibitors18. MTOR mutations have also been described as biomarkers for 
predicting tumour responses to mTOR inhibitors19,20.
Only rarely does single-agent therapy for cancer result in durable disease control. Patients with low 
BIM expression could derive only a meagre benefit from treatment with EGFR TKIs alone but could 
benefit from synthetic lethality combinations, including small molecules that mimic the BH3 motif. A 
previous study has demonstrated that gefitinib combined with the BH3 mimetic ABT-737 (an analog of 
navitoclax) substantially increases apoptosis compared with each agent alone in EGFR-mutant H1650 
cells with low BIM expression21. Selective Bcl-xL family inhibitors like venetoclax have improved safety 
and efficacy profiles, compared to their less selective predecessor, navitoclax22. Patients with high BIM 
expression could benefit from EGFR TKIs but analysis of MTOR could further improve outcomes by 
selecting patients with high MTOR for combination therapy with EGFR TKIs and mTOR inhibitors. 
Interestingly, the addition of an mTOR inhibitor to BH3 mimetics reduces the expression of the antia-
poptotic protein Mcl-1 and allows high BIM levels to “prime” tumour cells for apoptosis23.
A better understanding of the DGKα -PDE4-cAMP-mTOR pathway can indicate novel approaches to 
mTOR inhibition using DGKα or PDE4 inhibitors (Fig. 1)3,12–14. In the present study, in an exploratory in 
vitro analysis MTOR mRNA expression showed significant positive correlation with the PDE4D mRNA 
expression. By immunoblotting, mTOR expression was mainly related with PDE4D expression. Currently 
the effects of PDE4D in cancer are not fully understood and few studies have examined the role of 
Figure 4. Effect of gefitinib on BIM and mTOR expression. (a). PC-9 and H3255 cells were treated with 
DMSO vehicle and 5 nM or 50 nM of gefitinib for 24 hours. Lysates were prepared and run on gels for 
western blot with specific antibodies. Actin was used as the loading control. Incubation of cells with gefitinib 
induced a dose-dependent increase of BIM but did not change mTOR expression. (b) PC-9 cells were treated 
with indicated concentrations of gefitinib for 5 days. BIM and MTOR mRNA levels were assessed by qRT-
PCR. Incubation of PC-9 cells with gefitinib induced a dose-and time-dependent increase of BIM but did 
not affect MTOR mRNA expression. (c) 11–18. H1975 and H1650 cells were treated with DMSO vehicle and 
5 nM or 50 nM of gefitinib for 24 hours. Gefitinib did not induce BIM or inhibit mTOR expression in the 
gefitinib-sensitive 11–18 and the gefitinib-resistant H1975 and H1650 cells.
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PDE4D and its inhibitors in cancer therapy. A study revealed that hypoxia via hypoxia-inducible factor 
1α regulates PDE4D in lung cancer cell lines, including H1975, and treatment with the first-generation 
PDE4D inhibitor rolipram decreased cell proliferation14. Roflumilast is an oral PDE4 inhibitor used for 
patients with chronic obstructive pulmonary disease24.
The limitations of our study are its retrospective nature and small sample size which limit statistical 
power. However, the data presented herein provide important biological insights and may be used to 
refine the predictive role of BIM for outcomes to EGFR TKIs. Pretreatment levels of BIM and mTOR 
can lead to adding mTOR or PDE4 inhibitors to EGFR TKIs3. Also, it is tempting to speculate that PDE4 
could be a theranostic marker that warrants further research.
Methods
The Methods were carried out in accordance with the guidelines defined in the EURTAC study, which 
was approved by the Institutional Review Board of each participating centre. Written informed consent 
was obtained from all patients.
Gene expression analyses. All analyses were carried out centrally at the ISO 15189-certified Pangaea 
Biotech oncology laboratory located in the Quirón Dexeus University Hospital (Barcelona, Spain). Gene 
expression analysis of MTOR was performed on RNA isolated from the tumour tissue specimens and 
cell lines. Gene expression analysis of DGKA, PDE4A and PDE4D was performed on RNA isolated from 
the cell lines. RNA extraction, retrotranscription analysis, and RT-PCR were performed as previously 
described and gene expression was examined by quantitative PCR using β-actin as housekeeping gene25. 
BIM mRNA was previously assessed8 and BIM mRNA levels were available for 54 of 57 patients in the 
present analysis. MTOR mRNA assessment was possible in 48 patients. From the 50 patients of the 
validation cohort, 41 of them had sufficient material for mRNA expression. BIM and MTOR mRNA 
assessment was possible in 30 and 33 patients respectively.
Primers and probe for gene expression analysis of β-actin, MTOR, DGKA, PDE4A and PDE4D were 
designed according to their Ref Seq in http://www.ncbi.nlm.nih.gov/sites/entrez?db= gene (Supplementary 
Table 3). Gene expression of BIM was analysed with Hs00708019_s1 (Applied Biosystems).
Immunohistochemistry. Immunohistochemistry of the tumour samples was performed on 3 μ m 
sections using an automated immunostainer (Ventana BenchMark ULTRA, Ventana Medical Systems). 
The settings included pretreatment with cell conditioner 1 (CC1) buffer for 76 min, incubation with a 
BIM antibody (clone Y36, Abcam, ab32158; dilution 1:100) for 40 min, and pretreatment with CC1 buffer 
for 36 min, incubation with a P-S6 antibody (clone D68F8, Cell Signaling #5364; dilution 1:2000) for 
Figure 5. Effect of gefitinib treatment on mTOR signalling. Cells were treated with DMSO vehicle 
and 5 nM or 50 nM of gefitinib for 24 hours. Lysates were prepared and run on gels for Western blot 
with phosphorylation-specific antibodies. Actin was used as the loading control. (a) Effect of gefitinib on 
P-mTOR and P-p70S6K in PC-9 and H3255 sensitive cells. Inactivation of P-mTOR on the Ser2448 site and of 
P-p70S6K on the Thr389 was observed. (b) Effect of gefitinib on P-mTOR and P-p70S6K in the less gefitinib-
sensitive 11–18 and the gefitinib-resistant H1975 and H1650 cells. Maintenance of P-mTOR on the Ser2448 
site and of P-p70S6K on the Thr389 was observed after gefitinib treatment in 11–18 and H1975 cells, while 
suppression of phosphorylation was achieved with the 50nM of gefitinib in H1650 cells.
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20 min. The detection was performed with DAB detection kit (Ventana Medical Systems) according to 
manufacturer instruction. Slides were counterstained with hematoxylin and mounted. BIM staining was 
considered positive when either strong (3+ ) or moderate (+ 2) cytoplasmic staining was observed. P-S6 
staining was considered positive when only strong (3+ ) cytoplasmic staining was observed. In addition, 
protein expression was quantified using the histoscore (HS) method. Briefly, each tumour specimen was 
scored on a semiquantitative scale ranging from 0 to 300, with the final score resulting from the percent-
age of tumour cells staining positively (range 0–100) multiplied by staining intensity graded as negative, 
weak, moderate or strong (range 0–3). The median HS value was used as a cutoff level to discriminate 
high vs low expression of each biomarker.
Cell lines. H3255 and 11–18 human lung tumour cell lines were kindly provided by Dr. Daniel 
Costa (Department of Medicine, Harvard Medical School, Boston, MA) and Dr. Mayumi Ono (Kyushu 
University, Fukuoka, Japan), respectively. PC-9 human lung tumour cell line was kindly provided by F. 
Hoffmann-La Roche Ltd. with the authorization of Dr. Mayumi Ono. H1975 and H1650 human lung 
tumour cell lines were obtained from the American Type Culture Collection (ATCC) collection. Gefitinib 
was obtained from Selleckchem (USA). A 100 mM stock solution in Dimethylsulfoxide (DMSO) was 
prepared and stored at − 20 °C. All tissue culture materials were obtained from Biological Industries 
(Kibbutz Beit Haemek, Israel) or Invitrogen (Paisley, Scotland, United Kingdom).
All cell lines were maintained in RPMI medium supplemented with 10% FBS, 50 μ g/mL 
penicillin-streptomycin and 2 mM L-Glutamine. All cells were grown in a humidified atmosphere with 
5% CO2 at 37 °C. EGFR exons 19 and 21 of all cell lines were sequenced to confirm their status. Cell via-
bility was assessed by the Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma, St Louis, MO) assay. Cells 
from each cell line were seeded at 2000 to 6000 per well in 96-well plates. The concentration of gefitinib 
required for IC50 after a 72 h treatment was assessed. After treatment, cells were incubated with medium 
containing MTT (0.75 mg/mL in medium) for 1–2 h at 37 °C. Culture medium with MTT was removed 
and formazan crystals reabsorbed in 100 μ L DMSO (Sigma, St. Louis, MO). Cell viability was determined 
by measuring absorbance at 590 nm using a microplate reader (BioWhittaker, Walkersville, MD).
Western Blotting. For Western blot assays, cells were cultured in cell culture flasks and left untreated 
or treated as indicated in each experiment. Cells were lysed in ice-cold RIPA buffer [20 mM Tris-HCl 
(pH:7.5), 150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% NP40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 μ g/ml leupeptin, 1 mM PMSF)]. After 
incubating for 20 minutes at 4 °C, the samples were centrifuged, and the supernatant was kept at—80 °C. 
Protein concentration was determined by bicinchoninic acid protein assay. Equal amounts of protein 
from each cell lysate (30 μ g/lane) were subjected to SDS polyacrylamide gel electrophoresis (SDS/PAGE) 
and transferred onto polyvinylidene difluoride membranes (Millipore, New Bedford, MA, USA). The 
membranes were blocked in Tris-buffered saline containing 5% fat free dry milk and then probed with 
primary antibodies at 4 °C overnight. After washing, the membrane was incubated with horseradish 
peroxidase-conjugated secondary antibodies for 2 hours at room temperature. Specific proteins were vis-
ualized with enhanced chemiluminescence detection reagent according to the manufacturer’s instruc-
tions (Pierce Biotechnology, Rockford, IL, USA). The following antibodies used were from Cell Signaling: 
BIM (catalog no. 2819), total mTOR (catalog no. 2983), phospho-mTOR [ser2448] (catalog no. 5536) 
and phospho-P70S6 [thr389] (catalog no. 9234). Other antibodies were Actin (Sigma-Aldrich); DGKa 
(Abcam, ab197249); PDE4A (Abcam, ab125674); PDE4D (Abcam, ab14613).
Statistical analysis. The primary endpoint of the study was to examine the potential effects of BIM 
and MTOR mRNA expression levels on survival. On December 9th 2013, 135 PFS events had occurred 
and the results reported here are based on data analyses from that cutoff date. For the OS analysis, 
patients were not censored at crossover, whereas all patients were censored at crossover for the analysis 
of PFS. PFS and OS were estimated by means of the Kaplan–Meier method and compared with a non-
parametric log-rank test. Based on our previous experience26–28, in addition to analysing gene expression 
as a continuous variable, expression levels were divided into three groups according to their tertiles 
(inter-quartile ranges [Q1–Q3] were used to describe the data) to explore the risk trend of the gene varia-
ble and easily identify groups of gene expression with different risk. A multivariate Cox proportional haz-
ard model was applied with treatment and potential risk factors as covariates, obtaining HRs and their 
95% CI. Response rates were compared with the χ 2 test or Fisher exact test, as required. Each analysis 
was performed with the use of a two-sided 5% significance level and a 95% CI. Association between BIM 
expression levels and response was evaluated using logistic regression analysis. Association between bio-
markers was assessed using a Pearson correlation analysis. The correlation between immunohistochemi-
cal and RNA expression analysis has been investigated with the non parametric Mann-Whitney Wilcoxon 
Two-Sample test; significance was defined at the p < 0.05 level. The statistical analyses were performed 
using SAS version 9.3 and SPSS version 18.0. The EURTAC study is registered with ClinicalTrials.gov, 
number NCT00446225.
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